Rheumatoid arthritis: International disparities in access to anti-TNF therapy.
Where this comes from
- Record sourced from PubMed, PMID 21455248.
- Also identified by DOI 10.1038/nrrheum.2011.27.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The establishment of new benchmarks for treatment outcomes promises to drive great advances in rheumatoid arthritis therapy, but data on ‘real life’ experience with biologic therapy demonstrate that geographic location influences the stage of disease at which these agents are initiated.
Medical subject headings
- Anti-Inflammatory Agents, Non-Steroidal
- Antibodies, Monoclonal
- Arthritis, Rheumatoid
- Health Services Accessibility
- Healthcare Disparities
- Tumor Necrosis Factor-alpha